Vogels, C.B.F., Watkins, A.E., Harden, C.A., Brackney, D.E., Shafer, J., Wang, J., Caraballo, C., Kalinich, C.C., Ott, I.M., Fauver, J.R., Kudo, E., Lu, P., Venkataraman, A., Tokuyama, M., Moore, A.J., Muenker, M.C., Casanovas-Massana, A., Fournier, J., Bermejo, S., Campbell, M., Datta, R., Nelson, A., Dela Cruz, C.S., Ko, A.I., Iwasaki, A., Krumholz, H.M., Matheus, J.D., Hui, P., Liu, C., Farhadian, S.F., Sikka, R., Wyllie, A.L. and Grubaugh, N.D. (2021) SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity. Med (New York, N.Y.), 2, 263-280.e6.
https://doi.org/10.1101/2020.08.03.20167791

has been cited by the following article:

• TITLE: Validation of Microchip Based RT-PCR ABC Test (InfA/B & COVID-19) in Clinical Samples

  AUTHORS: Gabriel Martinez, Ryan Nunley, Michelle Gaines, Timea Majoros, Rajwant K. Gill, Irina Gelimson, Natallia Varankovich, Maxim Slyadnev, Sikander S. Gill

  KEYWORDS: SARS-CoV-2, Influenza, Multiplex, Microchip PCR, Nasal Swab and Saliva

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.8, August 23, 2022

  ABSTRACT: To contain the rapid and global spread of SARS-CoV-2, it is essential to develop an accurate and sensitive test system to address pandemic bottlenecks, simplified sample collection, and no sample prep. While meeting the demand of testing large populations, the miniaturized volume of assay reagents and offering rapid results is the need in such scenarios. Moreover, in view of the reports of co-infections and overlapping symptoms of Influenza caused by Influenza A or Influenza B, and COVID-19 caused by SARS-CoV-2, a test system with three targets can be supportive for accurate clinical diagnosis. In this presentation, we evaluated the performance of a test comprising Microchip RT-PCR Influenza and COVID-19 Detection System for identifying these three viral pathogens in nasal swabs and saliva specimens. A rapid and simplified total nucleic acid extraction method was developed and validated for the reliable, high-throughput simultaneous detection of respiratory viruses causing Influenza (type A and type B viruses) and COVID-19 (SARS-CoV-2 virus) using the microchip-based AriaDNATM platform deriving the name ABC Test. The test system was evaluated using 81 nasal swab samples, 77 clinical saliva samples, 5 blind CAP reference samples, and RNA standards. The limit of detection (LoD) was assessed using SARS-CoV-2, Influenza A, and Influenza B RNA standards. The multiplex ABC Test microchip displayed LoD of 14 copies/μL for SARS-CoV-2 and approximately 26 copies/μL for Influenza A, and 140 copies/μL for Influenza B, respectively. The ABC Test offers rapid multiplex one-step RT-PCR in 32 minutes for 45 cycles as the miniaturized reaction of 1.2 μL offering a highly sensitive, robust, and accurate assay for the detection of Influenza A/B, and SARS-CoV-2.